A prospective study of 62 patients with relapsing-remitting multiple sclerosis (RRMS) treated with Glatiramer acetate (GA) was conducted to evaluate the value of baseline and treatment-modulated cytokines in predicting the clinical response to the drug after 2 years of therapy. There were 32 responders and 30 non-responders. GA upregulated Th2/regulatory cytokines and inhibited Th1 cytokines in sera or PBMC supernatants 3 and 6 months into treatment. We found two prognostic models with clinical utility. A model based on IL-18 at baseline, the change in TNFa from baseline to 3 months, the change in IL-4 from baseline to 6 months, and the change in the log of the ratio of TNFa/IL-4 from baseline to 6 months had an area under the curve (AUC) of 0.80. A high IL-18 level at baseline and a reduction of TNF-alpha over time are associated with a response to GA. Although the study identified predictive biomarkers of clinical response to GA, the results will need to be validated in other data sets.
Introduction
Glatiramer acetate (GA) is an approved drug for the treatment of relapsing-remitting (RR) multiple sclerosis (MS) and is effective in reducing relapse rate and disability accumulation (Martinelli et al., 2003; Mikol et al., 2008; Cadavid et al., 2009) . GA is generally well tolerated; however, response to the drug is variable. The therapeutic effect of GA is supported by the results of magnetic resonance imaging (MRI) findings from various clinical trials (Comi et al., 2001; Zivadinov et al., 2015; Khan et al., 2012) . However, to date there are no validated predictive biomarkers of response to GA treatment.
The exact mechanism of action of GA in MS is still unclear. Although we believe that mechanisms of action of GA do not seem to be antigen specific, or even multiple myelin antigen specific, we theorize that antigen-based therapy generating GA-specific immune responses seem to be a prerequisite for GA therapy. A possible initial mode of action of GA is associated with binding to MHC molecules and consequent competition with various myelin antigens for their presentation to T cells (Fridkis et al., 1999; Arnon et al., 1996) . A further aspect of its mode of action is the induction of T regulatory cells (T-regs) that presumably can migrate to the brain and lead to in situ bystander suppression (Dhib-Jalbut et al., 2003) . We and others have previously shown that GA treatment in MS results in the induction of GA-specific T cells with predominant Th2 phenotype both in response to GA and crossreactive myelin antigens (Chen et al., 2001; Weber et al., 2007; Aharoni et al., 2003) . Furthermore, the ability of GA-specific infiltrating cells to express anti-inflammatory cytokines such as IL-10 and transforming growth factor-beta (TGF-β) together with brain-derived neurotrophic factor (BDNF) seem to correlate with the therapeutic activity of GA in EAE (Sarchielli et al., 2007) .
Initial studies by Balabanov et al. also demonstrated that GAmonocyte activation through urokinase plasminogen activator receptor (uPAR) could be a possible mechanism of GA in relapsing remitting MS (Balabanov et al., 2001; Stern et al., 2008) . Subsequent studies indicated that GA induces immunomodulatory activity exerted by cells of monocytic lineage including antigen presenting cells (APC) through an increase in IL-10 and reduction in IL-12 and IL-1B.
In addition, most investigators currently believe that the immunomodulatory effect of GA is linked to its ability to alter T-cell differentiation, in particular promotion of Th2 polarized CD4 cells. These GAinduced cells are believed to mediate bystander immunosuppression through the induction of IL-10 producing T-regs (Stern et al., 2008) .
